Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Q-linea AB ( (SE:QLINEA) ).
Q-linea AB has announced that a prominent US level 1 University Hospital Trauma Center has adopted its ASTar system for routine clinical use, following a successful evaluation period. This adoption highlights the system’s advantages, such as full automation, high throughput, and a broad antibiotic panel, positioning Q-linea for further growth in the healthcare sector.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea is a Swedish company specializing in rapid antibiotic susceptibility testing systems, particularly the ASTar system, which aids in the treatment of bloodstream infections and sepsis. The company aims to accelerate antimicrobial therapies in hospitals, ensuring timely and effective patient care. Q-linea is headquartered in Uppsala, Sweden, with regional offices in Italy and the USA, and holds CE-IVD and FDA 510(k) clearances for its products.
Average Trading Volume: 14,769
Technical Sentiment Signal: Sell
Current Market Cap: SEK175M
For an in-depth examination of QLINEA stock, go to TipRanks’ Overview page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts